Blueprint Medicines Corp (NASDAQ:BPMC) Director Sells $1,124,482.70 in Stock

Blueprint Medicines Corp (NASDAQ:BPMC) Director Charles A. Rowland, Jr. sold 11,818 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $95.15, for a total value of $1,124,482.70. Following the transaction, the director now directly owns 11,818 shares in the company, valued at $1,124,482.70. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Blueprint Medicines stock opened at $90.29 on Thursday. The company has a quick ratio of 6.59, a current ratio of 6.59 and a debt-to-equity ratio of 0.27. The stock has a 50 day moving average of $84.94. The stock has a market cap of $4.53 billion, a PE ratio of -16.75 and a beta of 1.45. Blueprint Medicines Corp has a one year low of $44.58 and a one year high of $100.76.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.83) by ($0.15). The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.38 million. Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. Blueprint Medicines’s revenue for the quarter was down 23.2% on a year-over-year basis. During the same period last year, the firm earned ($1.29) earnings per share. As a group, sell-side analysts forecast that Blueprint Medicines Corp will post -7.76 earnings per share for the current year.

A number of brokerages recently weighed in on BPMC. Zacks Investment Research raised Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a report on Tuesday, April 30th. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Thursday, March 28th. BidaskClub cut Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 16th. ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 4th. Finally, Goldman Sachs Group reissued a “buy” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $105.83.

A number of institutional investors have recently made changes to their positions in BPMC. Hillhouse Capital Advisors Ltd. purchased a new position in Blueprint Medicines in the 4th quarter worth approximately $77,142,000. Norges Bank purchased a new position in Blueprint Medicines in the 4th quarter worth approximately $42,705,000. FMR LLC increased its stake in Blueprint Medicines by 5.3% in the 1st quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after purchasing an additional 346,738 shares during the period. Foresite Capital Management III LLC increased its stake in Blueprint Medicines by 133.8% in the 4th quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock worth $25,213,000 after purchasing an additional 267,682 shares during the period. Finally, Marshall Wace North America L.P. purchased a new position in Blueprint Medicines in the 1st quarter worth approximately $21,105,000. 97.46% of the stock is currently owned by institutional investors and hedge funds.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: Golden Cross

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.